Bioxcel therapeutics presents results from ongoing phase 2 trial of bxcl701 in combination with keytruda® in aggressive forms of prostate cancer at esmo

Bxcl701 plus keytruda® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mcrpc patients with adenocarcinoma

BTAI Ratings Summary

BTAI Quant Ranking